The clinical efficacy of subcutaneous specific immunotlierapy (SCIT) has been confirmed in many studies. SCIT is the only specific treatment of allergic disorders with documented long-term efficacy after termination. Based on the observation, that allergens are the main trigger factors of atopic diseases in childhood (e.g., in bronchial asthma and allergic rhinitis), the use of specific immunotherapy (SIT) should be considered at an early stage of the disease. Furthermore, clinical studies suggest that SIT alters the natural course of allergy in monosensitized children in preventing the development of new sensitizations.
Research Areas and Centers
- Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)